EGFR is closely associated with the development and advancement of solid tumors, establishing itself as a crucial therapeutic target, particularly in non-small-cell lung carcinoma (NSCLC), glioblastoma, colorectal, breast, gastroesophageal cancers and so on [82]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.